<DOC>
	<DOCNO>NCT02839902</DOCNO>
	<brief_summary>The purpose study explore effect 8-week treatment omega-3-acid ethyl ester lipid lipoprotein profile blood hyperlipidemic patient receive HMG-CoA reductase inhibitor use HPLC comparison control group patient treat omega-3-acid ethyl ester .</brief_summary>
	<brief_title>Exploratory Study Effects Omega-3-acid Ethyl Esters Lipid Lipoprotein Profile Blood</brief_title>
	<detailed_description>This study design explore effect omega-3-acid ethyl ester lipid lipoprotein profile blood hyperlipidemic patient receive hydroxymethylglutaryl-coenzyme A ( HMG-CoA ) reductase inhibitor comparison control group patient treat omega-3-acid ethyl ester unblinded manner use high performance liquid chromatography ( HPLC ) use highly-sensitive gel filtration column , technique analyze lipoprotein . Study participant give consent assess eligible eligibility assessment stratify factor `` fast triacylglycerol ( TG ; &lt; 300 mg/dL 300 mg/dL≤ ) age ( &lt; 65 year 65 years≤ ) start screen period '' allocate either group treat omega-3-acid ethyl ester group treat omega-3-acid ethyl ester ( 1:1 ratio ) .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>1 . Participants diagnose hyperlipidemia . 2 . Participants constantly receive HMGCoA reductase inhibitor stable dose least 4 week time inform consent . 3 . Participants fast TG 150≤ &lt; 400 mg/dL measure time inform consent Visit 1 ( Week 4 ) . 4 . Participants , opinion principal investigator investigator , capable understanding content clinical study comply study protocol requirement . 5 . Participants provide write informed consent prior conduction clinical study procedure . 6 . Participants age ≥20 year time inform consent Visit 1 ( Week 4 ) . 1 . Participants clinically significant hemorrhagic disorder ( e.g. , hemophilia , capillary fragility , gastrointestinal ulcer , urinary tract hemorrhage , hemoptysis , vitreous hemorrhage ) within 24 week prior inform consent , concurrently disorder . 2 . Participants thyroid disorder ( hyperthyroidism hypothyroidism ) within 24 week prior inform consent , concurrently disorder , orally receive therapeutic drug thyroid disorder . 3 . Participants type HMGCoA reductase inhibitor change within 12 week prior inform consent . 4 . Participants receive eicosapentaenoic acid ( EPA ) preparation EPA/docosahexaenoic acid ( DHA ) preparation ( include supplement ) within 12 week prior inform consent . 5 . Participants start antidyslipidemic agent within 4 week prior inform consent . 6 . Participants severe hepatic impairment ( e.g. , ChildPugh classification C ) 7 . Participants previously diagnose lipoprotein lipase deficiency apoprotein CII deficiency . 8 . Participants concurrently Cushing 's syndrome , uremia , systemic lupus erythematosus ( SLE ) , serum dysproteinemia . 9 . Diabetic participant currently receive thiazolidine insulin . 10 . Participants concurrently hypertension grade IIINote 1 ) . Note 1 : Participants systolic blood pressure ≥180 mm Hg diastolic blood pressure ≥110 mm Hg regardless treatment antihypertensive drug . 11 . Participants habitual drinker drink average 100 mL per day ( express term quantity alcohol ) , participant history drug abuse addiction . 12 . Pregnant , lactate postmenopausal woman . 13 . Participants history hypersensitivity allergy omega3acid ethyl ester . 14 . Participants participate clinical study 15 . Participants assess ineligible study principal investigator investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>